Prometheon has completed both privately funded and industry-sponsored large animal pilot studies of their needle-free insulin TruePatch™. Early results of testing completed in August 2016 had already confirmed that Prometheon's extended-wear insulin patch works to lower blood glucose levels in a type 1 diabetic mini-pig model. These studies compared patch vs. subcutaneous needle injection delivery of the long-acting insulin analogue called glargine (LANTUS®, BASALIN®). Glargine for administration by injection will soon be available as a biosimilar from several other global generics manufacturers. Similar studies with other generic and modified insulins will identify the ideal insulins to use in both long-acting (basal) and rapid-acting (bolus) insulin patches, as well as address the need for heat-resistant patches for use in warm weather climates or low-resource settings where refrigeration is not available for retail distribution or home storage.Read More
Dr.Stephen Hsu (CEO/CSO) presented on Prometheon R&D team's history-making studies of an optimized TopiconENDO™ human growth hormone patch formulation for needle-free extended-wear hormone replacement therapy in children and adults. He delivered his oral presentation at Europe's most prestigious international gathering of pediatric endocrinologists and scientists--the 53rd Annual ESPE Meeting (Dublin, Ireland). He has been invited to serve as an abstract reviewer for the 54th Annual ESPE Meeting (Barcelona, Spain).